Table 1.
Characteristics of the included trials
| CRAFT | ACT I | ACT II | ACT III | AVRO | Scene II | Simon et al. | Beatch and Mangal | Asia‐Pacific trial | |
|---|---|---|---|---|---|---|---|---|---|
| Year | 2004 | 2008 | 2009 | 2010 | 2011 | 2012 | 2016 | 2016 | 2016 |
| Design | Randomized, double‐blind, placebo‐controlled | Randomized, double‐blind, placebo‐controlled | Randomized, double‐blind, placebo‐controlled | Randomized, double‐blind, placebo‐controlled | Randomized, double‐blind, active‐controlled | Randomized, double‐blind, placebo‐controlled | Randomized, controlled | Randomized, placebo controlled | Randomized, double‐blind, placebo‐controlled |
| No. of patients | 56 | 336 | 161 | 262 | 232 | 54 | 100 | 197 | 111 |
| AF duration | 3–72 hr | 3 hr–45 days | 3–72 hr | 3 hr–45 days | 3–48 hr | 3–48 hr (atrial flutter) | No longer than 48 hr | 3 hr–7 days | 3 hr–7 days |
| Primary endpoint | Proportion of patients who converted to NSR within 30 min | Proportion of patients who converted to NSR within 90 min | Proportion of patients who converted to NSR within 90 min | Proportion of patients who converted to NSR within 90 min | Proportion of patients who converted to NSR within 90 min | Proportion of patients who converted to NSR within 90 min | Time to conversion of atrial fibrillation to NSR | Proportion of patients who converted to NSR within 90 min | Proportion of patients who converted to NSR within 90 min |
| Age, mean (SD), y | 64 | 62 (13) | 68 (7) | 62 (11) | 63 (11) | 68 (11) | 57 (15) | 62 (13) | 60 (13) |
| Gender, male/female | 34/22 | 234/336 | 121/40 | 178/84 | 146/86 | 36/16 | 68/32 | 121/76 | 67/44 |
| No. CAD (%) | NR | 68 (20) | 129 (80) | 31(12) | 52 (22) | NR | 7 (7) | 30 (15) | 11 (10) |
| No. CHF (%) | Excluded | 50 (15) | 51 (32) | 52 (20) | 46 (20) | NR | 99 (99) | Excluded | 8 (7) |
| Independent clinical events committee | Yes | Yes | Yes | Yes | Yes | Yes | No | Yes | Yes |